Senior Leadership


Our team is comprised of industry leaders with a common commitment: to translate scientific breakthroughs into meaningful advances in treatment for patients.


Senior Vice President, Chief Medical Officer, Interim CEO


Edward M. Kaye, M.D., has served as our Interim Chief Executive Officer since March 31, 2015 and as our Senior Vice President, Chief Medical Officer since June 2011.

Dr. Kaye was Group Vice President of Clinical Development at Genzyme Corporation, a biotechnology company, from April 2007 to June 2011, where he supervised the clinical research in the lysosomal storage disease programs and in the genetic neurological disorders. Prior to this, Dr. Kaye held various roles at Genzyme Corporation since 2001, including Vice President of Medical Affairs for Lysosomal Storage Diseases, Vice President of Clinical Research and Interim Head of PGH Global Medical Affairs. Dr. Kaye earned his B.S. in Biology from Loyola University and earned his M.D. at Loyola University Stritch School of Medicine. He received his Pediatric training at Loyola University Hospital, Child Neurology training at Boston City Hospital, Boston University, and completed his training as a Neurochemical Research Fellow (Geriatric Fellow) at Bedford VA Hospital, Boston University. Dr. Kaye was head of the section of Neurometabolism, Pediatric Neurology at The Floating Hospital for Children (Tufts University) and research fellow in gene therapy at Massachusetts General Hospital until 1996 when he moved to Philadelphia to become Chief of Pediatric Neurology and Director of the Barnett Mitochondrial Laboratory at St. Christopher’s Hospital for Children. In 1998, Dr. Kaye accepted the appointment as Chief of Biochemical Genetics at Children’s Hospital of Philadelphia and Associate Professor of Neurology and Pediatrics at the University Of Pennsylvania School Of Medicine until moving to Genzyme Corporation at the end of 2001.

Dr. Kaye continues as a Neurological Consultant at the Children's Hospital of Boston and is on the editorial boards of a number of journals including Journal of Child Neurology. He also previously served on the board of Annals of Neurology. Dr. Kaye is also on the Medical/Scientific Advisory Boards of the United Leukodystrophy Foundation, Spinal Muscular Atrophy Foundation, CureCMD, CureDuchenne, and the Prize4Life.


Senior Vice President, Technical Operations


Jayant Aphale, Ph.D., has served as our Senior Vice President, Technical Operations since December 2011.

From January 2011 to December 2011, Dr. Aphale served as the President of Apex CMC Advisors, LLC, a biotechnology consulting company. From January 2010 to November 2010, Dr. Aphale served as a Vice President at GlaxoSmithKline plc, a publicly traded pharmaceutical company, in Belgium leading new product introductions, cGMP scale-up of clinical material manufacturing, U.S. government interactions and global technology transfer of marketed vaccines. From June 2008 to January 2010, Dr. Aphale was the Vice President of Manufacturing and Process Sciences at Enobia Pharma Corp., a biopharmaceutical company, where he structured their CMO network and led technology transfer and scale-up of their lead product in the rare disease space. Before Enobia, from 2006 to May 2008, Dr. Aphale served as Vice President, Manufacturing Operations and Project Management at Acambis plc, a biotechnology company, where, besides managing cGMP manufacturing across multiple sites, he established and implemented business processes in project and portfolio management and in transitioning clinical manufacturing to commercial scale.

Dr. Aphale received his Ph.D. in Microbiology from The Ohio State University in 1992, a Master of Business Administration in Finance and Strategy from the University of North Carolina in 2002, is a certified project manager (PMP) as well as holds the U.S. regulatory affairs certification (RAC).


Vice President, Global Health Policy and Government Affairs


Diane Berry, Ph.D., has served as our Vice President of Global Health Policy and Government Affairs since December 2011.

Previously Dr. Berry worked for the federal government overseeing and implementing science and technology and public health activities, including CBRN defense efforts, across the legislative and executive branches. Dr. Berry served as a Subcommittee Staff Director and Senior Professional Staff Member for the House Committee on Homeland Security and worked at the Department of Homeland Security in the Office of Health Affairs in leadership roles including Chief Scientist, Director of Threat Characterization and Countermeasures, and Senior Biodefense Advisor. Previously Dr. Berry also served as a Senior Science Advisor at McKenna, Long, and Aldridge. She was a Science & Technology Policy Fellow through the American Association for the Advancement of Science.

Dr. Berry earned her Ph.D. in chemical engineering from Northwestern University and received her B.S. and M.S. in chemical/biochemical engineering from Tufts University.


Vice President, Global Commercial and Business Development


Bo Cumbo joined Sarepta in January 2013 and serves as our Vice President of Global Commercial and Business Development.  

From June 2010 to January 2013, Mr. Cumbo worked at Vertex Pharmaceuticals, a biopharmaceutical company, where he served as Vice President of Sales and Treatment Education for the launch of Incivek, one of the most successful drug launches in the history of U.S. pharmaceuticals.

Prior to working at Vertex, Mr. Cumbo worked for Gilead Sciences, a biopharmaceutical company, for nine years in multiple commercial roles supporting the HIV, HBV and Cardiovascular franchises.  Mr. Cumbo has experience in sales, marketing, national accounts, federal accounts, treatment education and commercial strategy, as well as in building effective teams for successful competitive launches.

Mr. Cumbo started his career at GSK and has over twenty years of pharmaceutical and biotechnology experience, with over ten specialty competitive launches during his career.  Mr. Cumbo received his Bachelor of Science in Medical Technology from Auburn University and is a board member of Clinical Supplies Management, Inc.


Senior Vice President, General Counsel


Ty Howton has served as our Senior Vice President, General Counsel and Corporate Secretary since November 2012.

From September 2011 to June 2012, Mr. Howton served as the Senior Vice President, Chief Legal Officer and as a member of the executive team at Vertex Pharmaceuticals Incorporated, a publicly-traded biotechnology company, and in this capacity he participated in the general management of the company and oversaw all aspects of the Vertex global legal and compliance departments. Mr. Howton served as Senior Vice President Legal from July 2012 to November 2012. Prior to his appointment as Chief Legal Officer at Vertex, Mr. Howton served as the Chief Compliance Officer from September 2009 to August 2011 and, in this capacity, he was responsible for designing and implementing the Vertex corporate compliance program as well as chairing the company's Corporate Compliance Committee. From 2003 to September 2009, Mr. Howton worked at Genentech, Inc., a biotechnology company, where he served in a number of legal roles before becoming the company's chief healthcare compliance officer in 2006. Prior to joining Genentech in 2003, Mr. Howton was a member of the Sidley Austin LLP corporate healthcare practice where he advised on corporate transactions involving life science companies and provided regulatory counsel.

Mr. Howton holds a B.A. from Yale University and a J.D. from Northwestern University School of Law.


Senior Vice President, Chief Financial Officer


Sandy Mahatme has served as our Senior Vice President, Chief Financial Officer since November 2012.

From January 2006 to November 2012, Mr. Mahatme worked at Celgene Corporation, a biopharmaceutical company, where he served in various roles, including Senior Vice President of Corporate Development, Senior Vice President of Finance, Corporate Treasurer and Head of Tax. While at Celgene, Mr. Mahatme built the treasury and tax functions before establishing the Corporate Development Department, focused on strategic, targeted initiatives including commercial development in emerging markets, acquisitions and licensing and global manufacturing expansion. Prior to working at Celgene, Mr. Mahatme worked for Pfizer Inc., a pharmaceutical company, for eight and a half years in senior roles in Business Development and Corporate Tax.

Mr. Mahatme started his career at Ernst & Young LLP where he advised multinational corporations on a broad range of transactions. Mr. Mahatme holds Master of Laws (LL.M.) degrees from Cornell Law School and NYU School of Law and is a member of the New York State Bar Association. Mr. Mahatme is also a board member of Flexion Therapeutics, Inc.


Vice President, Head of Operations


Gavin T. Malenfant has served as our Vice President, Head of Operations since May 2015.

Prior to Sarepta, Mr. Malenfant was Vice President, Head of Operations for Sanofi Genzyme R&D Center, a biotechnology company, from September 2010 to May 2015 where he managed the operations associated with research and development activities in support of the Genzyme Rare Disease business portfolio. Prior to this, Mr. Malenfant held various roles at Genzyme Corporation since 1996, including Head of Program Management for the Genzyme Rare Disease portfolio. In this position, Mr. Malenfant brought multiple products to market contributing to the $4.0 billion in annual sales generated by the Rare Disease business unit.

Previous to Genzyme, Mr. Malenfant held management and process development positions with RepliGen Corporation.

Mr. Malenfant received his B.S. from the University of Massachusetts at Boston.


Vice President, Medical Affairs and
Patient Advocacy


Dana R. Martin, PharmD, has served as our Vice President of Medical Affairs and Patient Advocacy since August 2015.

Prior to joining Sarepta Therapeutics, Dr. Martin served as Vice President, Global Medical Operations at Synageva BioPharma, working hand-in-hand with the healthcare and patient community to change the paradigm of clinical diagnostic testing for patients at high-risk for Lysosomal Acid Lipase Deficiency (LAL-D). Dr. Martin’s work was instrumental to the identification of LAL-D patients eligible for enrollment in Kanuma™ pivotal clinical trials and to facilitate physician-driven patient diagnosis on an on-going basis, globally. He also worked closely with patient advocacy leaders and patients and families to further disease education of healthcare providers and to advance discussions about newborn screening for the disorder.

Dr. Martin developed his career at Genzyme Corporation where he held various Clinical Research and Medical Affairs positions of increasing responsibility over a 12-year period in the Personalized Genetic Health business unit. During his tenure at Genzyme, he contributed to the clinical development and commercialization of Fabrazyme®, Myozyme® and Lumizyme®.

Dr. Martin holds a BS in Pharmacy and a Doctor of Pharmacy degree from The Massachusetts College of Pharmacy and Health Sciences (MCPHS) in Boston and completed training in Fabry’s disease in the Lysosomal Disorders and Neurogenetics Clinic at Massachusetts General Hospital. He currently serves on the Dean’s Advisory Council for the University of New England’s College of Pharmacy (UNE-COP) and is Adjunct Faculty for Doctor of Pharmacy students from UNE-COP and the University of North Carolina’s Eshelman School of Pharmacy.


Vice President, Regulatory Affairs and Quality


Shamim Ruff joined Sarepta in January 2013 as our Vice President, Regulatory Affairs and Quality.

Ms. Ruff's experience includes more than twenty-five years in the biopharmaceutical industry, working with a diverse range of therapeutics including small molecules, monoclonal antibodies, oncolytic viruses and oligonucleotides. Her expertise in both domestic and international Regulatory Affairs spans early and late development across multiple therapeutic areas, including Rare Diseases, Oncology, Hematology, Antivirals and Bone Therapy Areas and includes extensive interaction with multiple regulatory agencies globally, including FDA (CDER/CBER/CDRH), EMA/CHMP, Health Canada, and PMDA.

Prior to joining Sarepta, Ms. Ruff served as Vice President, Regulatory Affairs at Sanofi where she was Head of Oncology Regulatory Affairs, responsible for leading Global, European, and CMC Regulatory Affairs teams.  She previously held senior positions at Amgen, Abbott and AstraZeneca where she had global oversight for the development and filings of multiple compounds, some of which had companion diagnostics.  In addition, Ms. Ruff has significant experience leading the preparations for FDA Advisory Committee Meetings.

Ms. Ruff holds a Bachelor’s degree in Chemistry & Biology from the University of Leicester, UK, and a Master’s degree in Analytical Chemistry from the University of Loughborough, UK.  Additionally, she is a Chartered Chemist and Member of the Royal Society of Chemistry (CChem MRSC), and is also an active member of DIA, RAPS and ASCO.


Vice President, Discovery Research


Dr. Bruce Wentworth joined Sarepta in March 2015 as our Vice President, Discovery Research.

Dr. Wentworth’s career includes extensive R&D experience in the cell therapy and rare disease area. In his more than 20 years of industry experience at Genzyme and later Sanofi, he led discovery and translational research on burn wound and cardiac repair programs as well as multiple rare disease programs especially pertaining to muscle genetic diseases.

Most recently, before joining Sarepta, he served as a Senior Director for Rare Disease Research. He has published frequently on the uses of antisense oligonucleotides as well as antibodies in various genetic preclinical models.

Dr. Wentworth holds his Ph.D. from the University of Massachusetts Medical School B.A. and his M.A. from Boston University.


Vice President, Head of Human Resources


Joan Wood joined Sarepta from March 2012 to November 2013 as our Vice President, Head of Human Resources. She returned to resume this role at Sarepta in April, 2015.

During the intervening period Ms. Wood served as General Manager, Volunteer Organization at The Possible Project, a not-for-profit youth entrepreneurship program founded and supported by Boston-area biotechnology luminaries.

Prior to joining Sarepta, Ms. Wood served for ten years as Senior Vice President in the Human Resources team at Genzyme Corporation where she and her team facilitated development of a coaching culture and provided talent management and development support for international General Managers on all continents and Senior Team Leaders across the global Biomedical and Regulatory Affairs organizations. Ms. Wood served as a member of the cross-functional team that competed successfully to see Genzyme named as a Top 100 Place to work by Fortune Magazine. Previously, Ms. Wood oversaw nation-wide commercial capability development as a Senior Vice President in the U.S. Mutual Fund Group at Scudder Investments and also worked at Fidelity Investments.

Ms. Wood holds her B.A. from the University of St. Joseph and her Master’s degree from Boston University. She is a graduate of Greater Boston Executive Development Program at MIT’s Sloan School of Management.